In this webinar, gain valuable insights into achieving high-quality measures of pulmonary pressure in mice, with a focus on using the Millar pressure catheters.
Key Highlights:
- Learn effective calibration techniques for Millar pressure catheters.
- Explore strategies for accurate catheter placement to obtain reliable traces.
- Watch a recorded live demonstration of catheter implantation for practical insights.
Delve into different mouse models of pulmonary hypertension for comprehensive understanding.
Abstract:
This webinar aims to equip participants with essential knowledge for measuring right ventricular pressure in mouse models of pulmonary hypertension, using the Millar Pressure Catheters. This session will cover calibration techniques, catheter positioning strategies, and approaches to ensure low variability in measurements. A recorded live demonstration of catheter implantation will be a key highlight, offering a practical understanding of the procedures discussed. Additionally, the webinar will explore various mouse models of pulmonary hypertension and compare methods for testing novel therapies against standard care approaches.
About the speakers:
Barbara Kemp-Harper
Associate Professor
Monash University
Barbara Kemp-Harper is Co-Director of the Pre-clinical Medicine Program at Monash University and Co-leads the Cardiovascular & Pulmonary Pharmacology Group in the Department of Pharmacology. Barbara received her PhD in cardiovascular pharmacology from Monash University in 1995 and following receipt of a NHMRC CJ Martin Fellowship, undertook post-doctoral training at the Wolfson Institute for Biomedical Research, London with Professor Salvador Moncada. Barbara has an established international reputation in the field of vascular pharmacology. She has extensive experience in pre-clinical models of systemic and pulmonary hypertension and her research aims to identify novel strategies for the prevention and treatment of systemic and pulmonary vascular disease with a focus on the nitric oxide/cGMP signaling pathway and inflammation. Her international standing is highlighted by her nomination as the Robert F. Furchgott Lecturer (Nobel Laureate) at the 14th International Symposium on Mechanisms of VasoDilatation (Hong Kong, 2021) and appointment as an Editor.
Dr. Kristen Bubb
Group Leader
Monash University
Dr Kristen Bubb is Lead of the Translational Vascular Therapeutics Group in the Biomedicine Discovery Institute at Monash University. Kristen obtained her PhD at Monash University in 2010, before completing a post-doctoral fellowship at the William Harvey Research Institute in London, supported by the British Pharmacological Society. She then co-led a research program to investigate novel therapeutics and signaling pathways applicable to vascular diseases at the University of Sydney, before being recruited to Monash University in 2019 to establish the founding laboratory in the Victorian Heart Institute. Her main research interests are to investigate inflammatory and redox signaling in vascular diseases, with the aim of developing novel therapeutics for atherosclerosis, pulmonary hypertension and pre-eclampsia. Kristen has over a decade of experience in measuring right ventricular function and pressure in mouse models of pulmonary hypertension. Kristen has published many high-quality manuscripts on novel therapies for pulmonary hypertension, book chapters on cyclic GMP/phosphodiesterases and redox signaling and has been invited to present her work on novel PH therapeutics at national and international conferences (i.e. The World Microcirculation congresses in 2015 [Kyoto] and 2023 [Beijing] and the High Blood Pressure Research Council of Australia in 2022).
Peng-Cheng Wang (Stan)
PhD Candidate
Monash University
Peng-Cheng Wang (Stan) is a PhD candidate in the Department of Pharmacology, Biomedicine Discovery Institute, Monash University under the supervision of A/Prof. Barbara Kemp-Harper. He was granted a Master of Science in 2013 (Taipei Medical University) and has worked in academia as a research assistant and in industry as a sales representative. He is a recipient of co-funded Monash Graduate Scholarship, Faculty International Tuition Scholarships and Graduate Research Completion Award during his PhD. Stan’s PhD research focuses on new cell-based therapeutic strategies for the treatment of pulmonary hypertension (PH), and thesis is titled “Investigating the therapeutic utility of human amniotic epithelial cell-derived exosomes in pulmonary hypertension”. His PhD research program is involved in the use of a pre-clinical murine model of PH (Sugen/ hypoxia). The endpoint hemodynamic measurements in this pre-clinical model including right ventricular systolic pressure (via Millar catheter) and mean arterial blood pressure measurements together with histological and molecular analysis to examine pulmonary and cardiac remodeling and inflammation.